title: Peripheral blood stem cell transplantation after high-dose therapy in patients with malignant lymphoma: a retrospective comparison with autologous bone marrow transplantation.
abstract: We report the results of peripheral blood progenitor cell (PBPC) harvesting in 22 patients with lymphoma who underwent leucapheresis after cells were mobilised using 3 g/m2 cyclophosphamide and G-CSF. In 19 patients, the total CFU-GM collected was greater than 7.5 x 10(4)/kg. These patients underwent successful autologous PBPC transplantation. This group of patients was compared to a historical group of 24 patients with lymphoma who underwent ABMT with the same conditioning chemotherapy. The time to engraftment of neutrophils to 0.5 x 10(9)/l was significantly reduced (median 11 days vs 19 days, P < 0.0001) and consequently in-patient stay was reduced (median 21 days vs 28 days, P < 0.001). Blood product support (median 3 vs 4 units blood, P = 0.02; median 15 vs 40 units platelets, P = 0.005) and use of TPN (median 0 days vs 8 days, P < 0.001) were reduced. We estimate a saving of approximately pounds 2370 per patient using PBPC for autologous transplantation compared to bone marrow progenitor cells. This saving is significant (P < 0.001).
authors.affiliation: Department of Haematology, Addenbrooke's NHS Trust, Cambridge, UK.
authors.forename: S
authors.initials: S
authors.lastname: Ager
authors.forename: M A
authors.initials: MA
authors.lastname: Scott
authors.forename: P
authors.initials: P
authors.lastname: Mahendra
authors.forename: E M
authors.initials: EM
authors.lastname: Richards
authors.forename: H K
authors.initials: HK
authors.lastname: Jestice
authors.forename: P
authors.initials: P
authors.lastname: Boraks
authors.forename: T P
authors.initials: TP
authors.lastname: Baglin
authors.forename: R E
authors.initials: RE
authors.lastname: Marcus
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation / Q000191:economics; D003131:Combined Modality Therapy / Q000191:economics; D003365:Costs and Cost Analysis; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000191:economics; D006801:Humans; D008223:Lymphoma / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D014182:Transplantation, Autologous